Improved Hemoglobin Status and Reduced Menstrual Blood Loss among Female Carriers of Factor V Leiden – An Evolutionary Advantage?

Thromb Haemost 2001; 86(04): 1122-1123
DOI: 10.1055/s-0037-1616547

Letters to the Editor

Schattauer GmbH

Authors

Pelle G. Lindqvist

¹Departments of Obstetrics and Gynecology, Sweden
Bengt Zöller

²Coagulation Disorders, Lund University, University Hospital, Malmö, Sweden
Björn Dahlbäck

²Coagulation Disorders, Lund University, University Hospital, Malmö, Sweden

References
1 Bertina RM, Koelemann BP, Koster T. et al. Mutation in blood coagulation factor V associated with resistance to activated protein. C. Nature 1994; 369 3475 64-7.
2 Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism charactedrized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90 (Suppl. 03) 1004-8.
3 Dahlbäck B. Blood coagulation. Lancet 2000; 355 9215 1627-32.
4 Högberg U, Broström G. The demography of maternal mortality-seven Swedish parishes in the 19th century. Int J Gynaecol Obstet 1985; 23 (Suppl. 06) 489-97.
5 Lindqvist PG, Svensson PJ, Marsal K, Grennert L, Lutherkort M, Dahlbäck B. Activated protein C resistance (FV:Q506) and pregnancy. Thromb Haemost 1999; 81: 532-7.